Head and neck oncology: What the past decade has taught us

Expert Review of Anticancer Therapy

Volumn 6, Issue 9, 2006, Pages 1133-1136

  Bernier, Jacques ^a  

^a Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; OXALIPLATIN; PALIFERMIN; PANITUMUMAB; TAXANE DERIVATIVE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; EDITORIAL; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT FAILURE;

COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33750086948     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.1133     Document Type: Editorial

References (13)

1. Horiot JC, Le Fur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotheraphy. Radiother. Oncol. 25(4), 231-241 (1992).
2. Horiot JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol. 44(2), 111-121 (1997).
3. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer. A systematic review of the published literature with subgroup analysis. Head Neck 23, 579-589 (2001).
4. Bernier J, Bentzen SM. Altered fractionation and combined radiochemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur. J. Cancer 39(5), 560-571 (2003).
5. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck cancer squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355, 949-955 (2000).
6. Bernier J, Domenge C, Ozsahin M et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1945-1952 (2004).
7. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiochemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
8. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck 27, 843-850 (2005).
9. Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat. Clin. Prac. Oncol. 2(6), 305-314 (2005).
10. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl Cancer Inst. 88(13), 890-899 (1996).
11. Vermorken JB, Remenar E, van Herpen J et al. Standard cisplatin/ infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a Phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J. Clin. Oncol. 22(Suppl.), 490S (2004).
12. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11(4), 689-708 (2004).
13. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (6), 567-578 (2006).